SCHEMBL31397484

SCHEMBL31397484

COC(=O)Cn1nc(C)c2cc(-c3ccc4c(c3)n(C)c(=O)n4-c3ccc(OCc4ccccc4)nc3OCc3ccccc3)ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.38
▸ LMNA P02545 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CYP1A2 P05177 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ PKM P14618 1/20 0.34
▸ TSHR P16473 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.33
▸ PDE5A O76074 2/20 0.33
▸ SRD5A2 P31213 1/20 0.33
▸ HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31397230 0.94 PKM (0.36) KMT2APKMNPC1RAB9AHSD17B10
SCHEMBL31397088 0.84 PKM (0.37) SMN1; SMN2KMT2APKMNPC1RAB9A
SCHEMBL24821044 0.84 PKM (0.37) SMN1; SMN2KMT2APKMNPC1RAB9A
SCHEMBL31397573 0.84 TSHR (0.38) MAPTLMNAALDH1A1HTTKMT2A
SCHEMBL31397527 0.83 FFAR1 (0.36) KDM4EALDH1A1CYP1A2PKMSRD5A2
SCHEMBL31397431 0.82 FFAR1 (0.38) KDM4EPKMGRM5
SCHEMBL31397116 0.81 SYK (0.37) MAPTLMNASMN1; SMN2KDM4EKMT2A
SCHEMBL31397574 0.80 NR4A2 (0.46) PKMTSHRHDAC1HDAC8GRM5
SCHEMBL31397430 0.79 FFAR1 (0.41) PKMSRD5A2GRM5
SCHEMBL31397542 0.79 PKM (0.40) MAPTSMN1; SMN2KMT2AGAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240424111-A1 Degrader Compounds and Uses Thereof CALICO LIFE SCIENCES LLC (US) 2024-12-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240424111-A1 Degrader Compounds and Uses Thereof PTPN1, PTPN2, PTPN5 MAPT 2667/4885LMNA 4769/4885SMN1; SMN2 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback